FLOVENT HFA

Fluticasone

FLOVENT HFA

ICS MDI

Fluticasone propionate · GlaxoSmithKline

Clinical Reference

Active Medication & Mechanism

Fluticasone propionate ICS
44 mcg, 110 mcg, or 220 mcg per actuation

Synthetic corticosteroid with potent anti-inflammatory activity. Reduces airway inflammation by suppressing inflammatory cell recruitment and cytokine production.

FDA-Approved Dosing by Indication

// approval varies by strength + age

Asthma

3/4 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
44 mcg	Patients ≥4 years	2 inhalations twice daily (~12 hours apart) Starting dose for patients previously on bronchodilators alone.	176 mcg	FDA Approved
110 mcg	Patients ≥12 years	2 inhalations twice daily For patients previously on ICS. Recommended starting dose for patients ≥12.	440 mcg	FDA Approved
220 mcg	Patients ≥12 years	2 inhalations twice daily Maximum dose for patients previously on oral corticosteroids.	880 mcg	FDA Approved
Any strength	Acute bronchospasm	—	—	Not Approved Not a bronchodilator. Not for acute bronchospasm. Use a SABA.

44 mcg FDA Approved

Pop · Patients ≥4 years

2 inhalations twice daily (~12 hours apart)

Starting dose for patients previously on bronchodilators alone.

Total · 176 mcg
110 mcg FDA Approved

Pop · Patients ≥12 years

2 inhalations twice daily

For patients previously on ICS. Recommended starting dose for patients ≥12.

Total · 440 mcg
220 mcg FDA Approved

Pop · Patients ≥12 years

2 inhalations twice daily

Maximum dose for patients previously on oral corticosteroids.

Total · 880 mcg
Any strength Not Approved

Pop · Acute bronchospasm

—

Total · — Not a bronchodilator. Not for acute bronchospasm. Use a SABA.

Acute Use

0/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
Any strength	Acute bronchospasm / rescue	—	—	Not Approved Not for acute relief. Use a SABA.

Any strength Not Approved

Pop · Acute bronchospasm / rescue

—

Total · — Not for acute relief. Use a SABA.